###begin article-title 0
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Chronic myelomonocytic leukemia (CMML) is a hematological disease close to, but separate from both myeloproliferative disorders (MPD) and myelodysplastic syndromes and may show either myeloproliferative (MP-CMML) or myelodysplastic (MD-CMML) features. Not much is known about the molecular biology of this disease.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 105 113 <span type="species:ncbi:9606">patients</span>
We studied a series of 30 CMML samples (13 MP- and 11 MD-CMMLs, and 6 acutely transformed cases) from 29 patients by using Agilent high density array-comparative genomic hybridization (aCGH) and sequencing of 12 candidate genes.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 183 186 183 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF1</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK6</italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 297 304 297 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 506 512 506 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 515 520 515 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16</italic>
###xml 522 526 522 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 530 536 530 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 648 654 648 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
Two-thirds of samples did not show any obvious alteration of aCGH profiles. In one-third we observed chromosome abnormalities (e.g. trisomy 8, del20q) and gain or loss of genes (e.g. NF1, RB1 and CDK6). RAS mutations were detected in 4 cases (including an uncommon codon 146 mutation in KRAS) and PTPN11 mutations in 3 cases. We detected 11 RUNX1 alterations (9 mutations and 2 rearrangements). The rearrangements were a new, cryptic inversion of chromosomal region 21q21-22 leading to break and fusion of RUNX1 to USP16. RAS and RUNX1 alterations were not mutually exclusive. RAS pathway mutations occurred in MP-CMMLs (~46%) but not in MD-CMMLs. RUNX1 alterations (mutations and cryptic rearrangement) occurred in both MP and MD classes (~38%).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 91 103 91 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
We detected RAS pathway mutations and RUNX1 alterations. The latter included a new cryptic USP16-RUNX1 fusion. In some samples, two alterations coexisted already at this early chronic stage.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 358 359 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 663 664 663 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Chronic myelomonocytic leukemia (CMML) is a heterogeneous hematopoietic disease currently classified by the WHO organization as an entity close to, but separate from both myeloproliferative disorders (MPD) and myelodysplastic syndromes. CMML is included in the category of MPD/MDS diseases and defined by persistent peripheral monocytosis greater than 1 x 109/L, fewer than 20% blasts in the blood or bone marrow (BM), and BM dysplasia in one or more myeloid lineage. Because the blast number is a prognostic factor, CMML is divided in two types: type 1 with fewer than 5% in blood and 10% blasts in BM, and type 2 between 5 and 19% in blood or 10 and 19% in BM [1,2].
###end p 11
###begin p 12
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
The problem of CMML resides in its classification and in the clinical and/or biological relevance of separating the proliferative and dysplastic presentations. The FAB system has recommended a division of CMML in two classes upon leucocyte count: leucocytosis < 13 x 109/L defines CMML as MDS-like (MD-CMML) and leucocytosis > 13 x 109/L as MPD-like (MP-CMML) [2]. The two classes have been variably associated with prognosis and their distinction is a matter of debate [3-7]. This reflects that, except in few imatinib-sensitive cases with PDGFRB alterations, the pathogenesis of CMML is poorly understood. Consequently, the definition and therapy of CMML remain unsatisfactory.
###end p 12
###begin p 13
To better understand CMML and improve its classification we have studied the genome of a series of CMML samples by using genome-wide, high-density array-comparative genomic hybridization (aCGH) and DNA sequencing of candidate genes.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and samples
###end title 15
###begin p 16
###xml 481 482 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 605 606 605 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 136 144 <span type="species:ncbi:9606">Patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 695 703 <span type="species:ncbi:9606">patients</span>
A consecutive series of 30 BM samples were collected from 29 patients including 24 CMMLs and 6 acute transformations of CMML (AT-CMML). Patients were newly diagnosed or were known for hematopoietic disease and the therapeutic impact was evaluated every 3 months. Three patients (3, 52, 90) had received prior chemotherapy for an independent solid tumor. One had an 11q inversion and one had a t(1;3). Clinical and biological data of the 30 samples are presented in Additional file 1. Cytology and phenotype were assessed by three specialists (VGB, CA, DS). Nucleic acids extraction was done as described [8]. Gene expression profiles for the cases with available RNA have been reported [8]. The patients all signed an informed consent. The project and collection of samples were reviewed by the independent scientific review board of the Paoli-Calmettes Institute (COS), in accordance with current regulations and ethical concerns.
###end p 16
###begin title 17
Array comparative genomic hybridization (aCGH)
###end title 17
###begin p 18
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 414 416 414 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 484 486 484 486 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 621 622 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 623 625 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Genomic imbalances were analyzed by aCGH using 244 K CGH Microarrays (Hu-244A, Agilent Technologies, Massy, France) as previously described [9,10]. The resolution is up to 6 kb. Scanning was done with Agilent Autofocus Dynamic Scanner (G2565BA, Agilent Technologies). Data analysis was made as previously described [10,11] and visualized with CGH Analytics 3.4 software (Agilent Technologies). Extraction data (log2 ratio) was done with CGH analytics while normalized and filtered log2 ratio were obtained from << Feature extraction >> software (Agilent Technologies). Copy number changes were characterized as reported [9,10].
###end p 18
###begin p 19
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 341 345 341 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 277 282 <span type="species:ncbi:9606">human</span>
###xml 514 519 <span type="species:ncbi:9606">human</span>
The RUNX1 gene map established within Mb scale was extracted from the build 36.1 from NCBI (March 2006 version) while its sequence (Ensembl Transcript ID ENST00000300305) was extracted from Ensembl database , which is based on the Ensembl release 48 - Dec 2007 assembly of the human genome. Genomic profile was established with CGH analytics(R) software (Agilent Technologies), from centromere to telomere, within the genomic intervals [28.0-30.5 Mb] and [33.8-36.3 Mb] of the short arm of the chromosome 21 (hg17 human genome mapping; build 35 from NCBI, May 2004 version).
###end p 19
###begin title 20
DNA sequencing
###end title 20
###begin p 21
###xml 21 87 21 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF, JAK2, HRAS, KRAS, NRAS, NF1, RAF1, RB1, RUNX1, SOS1, SPRED1 </italic>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11 </italic>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
Somatic mutations of BRAF, JAK2, HRAS, KRAS, NRAS, NF1, RAF1, RB1, RUNX1, SOS1, SPRED1 and STK11 genes were searched by sequencing exons and consensus splicing sites after PCR amplification of genomic DNA (Additional file 2). Most PCR amplifications were done in a total volume of 25 mul PCR mix containing at least 10 ng template DNA, Taq buffer, 200 mumol of each deoxynucleotide triphosphate, 20 pmol of each primer and 1 unit of Hot Star Taq (Qiagen). PCR amplification conditions were as follows: 95degreesC 10 min; 95degreesC 30 sec, variable temperature 30 sec, 72degreesC 45 sec for 30 cycles; 72degreesC 10 min. PCR products were purified using Millipore plate MSNU030.
###end p 21
###begin p 22
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
Two microliters of the purified PCR products were used for sequencing using the Big Dye terminator v1.1 kit (Applied Biosystems). After G50 purification, sequences were loaded on an ABI 3130XL automat (Applied Biosystems). The sequence data files were analyzed using the SeqScape software (Additional file 2) and all mutations were confirmed on an independent PCR product.
###end p 22
###begin title 23
PCR detection of RUNX1 alterations
###end title 23
###begin p 24
###xml 4 16 4 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
The USP16-RUNX1 gene fusion was detected by using nested PCR amplification of retrotranscribed mRNA (RT-PCR) from BM cells of the patients as previously described [12]. Wild-type and fusion transcripts were amplified using RUNX1 and USP16 primer sequences (Additional file 3). PCR products were visualized on agarose gel with ethidium bromide, and sequenced.
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
Three types of aCGH profiles in CMML
###end title 26
###begin p 27
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 675 679 675 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF1 </italic>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 723 729 723 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 749 755 749 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALN1 </italic>
###xml 810 815 810 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK6 </italic>
###xml 913 917 913 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Using genome-wide, high-density arrays we established the aCGH profiles of 30 samples from 29 patients, comprising 24 CMMLs and 6 AT-CMMLs. Examples of profiles are shown in Figure 1 and results are summarized in Table 1. Three main types of profiles were observed. Type 1 profiles showed gains or losses visible on the karyotype and affecting large regions of the genome, such as trisomy 8 (10%: cases 5, 12 and 88), deletions of part of the 20q arm (10%: cases 3, 74, and 96), or deletion (case 106) or complex rearrangements of chromosome 7 (case 3). Type 2 profiles showed rare and limited gains or losses that affected few or single genes such as deletions encompassing NF1 at 17q11 (case 80), RB1 at 13q14 (case 74), RUNX1 at 21q21 (case 88), CALN1 at 7q11 (case 12), amplification of 7q21 including the CDK6 gene (case 3) or a series of short deletions on the 3q arm (case 1). A surprising deletion of the MYC locus was observed in case 106. The type 3 profile was said "normal-like" since no obvious alteration was detected. It occurred in two-thirds of the cases.
###end p 27
###begin p 28
###xml 0 25 0 25 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Examples of aCGH profiles</bold>
###xml 107 110 107 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF1</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 418 425 <span type="species:ncbi:9606">patient</span>
Examples of aCGH profiles. A: aCGH profile of chromosome 17 in case 80. Red arrow shows deletion including NF1. B: aCGH profile of chromosome 13 in case 74 showing RB1 deletion. For a and b, a zoom of the region is shown to the right of the profiles. C: aCGH profile of chromosome 3 in case 1 showing a series of deletions at 3q. D: aCGH profiles of chromosome 20 in cases 3, 37, 74 and 96 (3 and 37 are from the same patient).
###end p 28
###begin p 29
Molecular features of the 30 studied CMML
###end p 29
###begin p 30
###xml 60 61 60 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
CMMLs are classified by a double line as in Additional file 1.
###end p 30
###begin p 31
CMML: chronic myelomonocytic leukemia.
###end p 31
###begin p 32
AT-CMML: acute transformation of CMML in acute myeloid leukemia (all M4 FAB type).
###end p 32
###begin p 33
###xml 35 42 <span type="species:ncbi:9606">patient</span>
Samples 3 and 37 are from the same patient.
###end p 33
###begin p 34
In bold: myeloproliferative CMML.
###end p 34
###begin p 35
nd: not done.
###end p 35
###begin p 36
E: exon.
###end p 36
###begin p 37
Tri: trisomy.
###end p 37
###begin title 38
Mutations of RAS and RUNX1 genes
###end title 38
###begin p 39
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HRAS </italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NRAS </italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 352 359 <span type="species:ncbi:9606">patient</span>
We analyzed the sequences of the three RAS genes. No mutation of HRAS was found. NRAS mutations were found in cases 12 and 78, and KRAS mutations in cases 79 and 89 (Table 1). One of these mutations affected codon 146 in coding exon 3, a rare type of RAS mutation that has been found in 4% colorectal cancers and two hematopoietic cell lines [13]. For patient 79 we determined that the mutation was present in a heterozygous state in the CD34-purified fraction of the BM cells, in the polynuclear neutrophils, monocytes and B lymphocytes but absent in the T cells (data not shown).
###end p 39
###begin p 40
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAF1</italic>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOS1 </italic>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 367 372 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOS1 </italic>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 413 417 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF</italic>
###xml 444 451 444 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPRED1 </italic>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
We examined the sequence of exons 3 and 13 of the PTPN11 gene. Mutations were found in three cases. No mutation was found in exon 7 of RAF1, which is a hotspot for mutations in Noonan syndrome (NS) [14,15]. SOS1 and BRAF were also sequenced in their most frequently mutated regions (exons 7-11 and kinase-encoding exons, respectively). One mutation was identified in SOS1 in a region involved in NS [16], none in BRAF. No mutation was found in SPRED1 [17].
###end p 40
###begin p 41
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF1 </italic>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
The NF1 gene was analyzed for mutations in cases 79 and 80. A silent, so far unreported point mutation (c.2178G>C) was found in case 79 (Table 1). The deletion of an RB1 allele was confirmed by sequencing in case 74 and the remaining RB1 allele was normal. There was no JAK2 p.Val617Phe mutant in our panel of CMML cases.
###end p 41
###begin p 42
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Mutations were found in the RUNX1 gene in 10 patients (30%). Mutation in case 90 is predicted to induce neither amino acid change nor splicing effect and thus was not considered as functionally deleterious. The nine other nucleotide variations would result in truncated or mutant proteins. RUNX1 mutations are described in Figures 2 and 3.
###end p 42
###begin p 43
###xml 12 15 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS</italic>
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mutation of <italic>RAS</italic>, <italic>PTPN11 </italic>and <italic>RUNX1 </italic>genes in CMML</bold>
###xml 135 154 135 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS, PTPN11, SOS1 </italic>
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
Mutation of RAS, PTPN11 and RUNX1 genes in CMML. Examples of mutations in candidate genes. From top to bottom, sequence of the mutated KRAS, PTPN11, SOS1 and RUNX1 alleles, demonstrating base change in the forward sequence at the position indicated by an arrow. The corresponding sequence is shown above. Primers and conditions used are described in additional file 2.
###end p 43
###begin p 44
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of <italic>RUNX1 </italic>mutations in CMML patients</bold>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 498 504 498 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1</italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Characterization of RUNX1 mutations in CMML patients. A: Genomic organization of RUNX1 gene at 21q22.12 and RUNX1 protein. Functional (i.e. RUNT and RUNXI [for RUNX Inhibitor domain], as defined by PFAM accession numbers PF00853 and PF08504, respectively) and motifs of the RUNX1 protein were positioned according to the SMART program . Nucleotide (cDNA level) and deduced aminoacid sequences of the RUNX1 protein are positioned above and below the corresponding protein, respectively. The genomic RUNX1 sequence of CMML 5 exhibited a mutation in the consensus splicing sequence of intron 3. B: Mutations of RUNX1. All mutations but one introduced an aberrant stop codon (cases 3, 6, 12, 15 and 87). Two missense mutations (cases 1 and 25) were also observed. The mutations are located with respect to the modified aminoacid of the RUNX1 protein. C: Representation of putative mutated RUNX1 proteins. According to the SMART program, all putative modified proteins have lost their RUNT and RUNXI domains.
###end p 44
###begin p 45
###xml 38 49 38 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK11/LKB1 </italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SYK </italic>
Finally, no mutation was found in the STK11/LKB1 and SYK kinase genes.
###end p 45
###begin title 46
A novel, cryptic rearrangement of RUNX1 following inv(21q)
###end title 46
###begin p 47
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16</italic>
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCT8</italic>
###xml 190 196 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BACH1 </italic>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIK1 </italic>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 541 547 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 728 740 728 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 889 901 889 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 988 1000 988 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 1053 1065 1053 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 1086 1092 1086 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 1105 1111 1105 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 1290 1296 1290 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 1397 1409 1397 1409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 1468 1469 1468 1469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1494 1506 1494 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 1596 1602 1596 1602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 1605 1611 1605 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 1619 1620 1619 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1948 1949 1948 1949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1980 1986 1980 1986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 679 686 <span type="species:ncbi:9606">patient</span>
###xml 1040 1047 <span type="species:ncbi:9606">patient</span>
The aCGH profile of case 88 showed two losses at 21q21.3 and q22.12 of about 1.04 Mb and 0.82 Mb, respectively (Figure 4A). They spanned the 3' part of USP16, including exons 2 to 19, CCT8, BACH1 and GRIK1 as well as the 5' part of RUNX1 (including exons 1 to 4), respectively. We hypothesized that such a peculiar pattern could be due to a cryptic inv(21)(q21q22) associated with a microdeletion at one of the breakpoints. Given the features and orientation of the various potentially-involved genes, we surmise that a fusion could involve RUNX1 and USP16 (encoding a de-ubiquitinating enzyme). This was confirmed by nested PCR amplification of reverse-transcribed RNA from the patient's BM cells, which detected a 245 bp-long USP16-RUNX1 transcript (Figure 4B). No reciprocal transcript was detected. Sequence analysis showed that the result of the inversion/fusion generated a chimeric USP16-RUNX1 transcript. The break/fusion was not present in the germline since we did not find the USP16-RUNX1 transcript in buccal smear cells of the patient. The USP16-RUNX1 gene fuses exon 1 of USP16 to exon 5 of RUNX1 thus not preserving the canonical ATG codons. The chimeric transcript exhibited several stop codons in its 5' part but the presence of multiple ATG codons through exons 5 to 7 of RUNX1 sequence could be used as new start codons and generate putative truncated RUNX1 proteins. A similar USP16-RUNX1 fusion (without microdeletion) was found in CMML 34 (Table 1). In the two cases, the USP16-RUNX1 fusion transcripts did not have an open reading frame using the canonical start codons of USP16 or RUNX1 (Figure 5). According to the SMART program , functional domains (i.e. RUNT and RUNXI [for RUNX Inhibitor domain], as defined by PFAM accession numbers PF00853 and PF08504, respectively) should disappear in such putative truncated RUNX1 proteins. RUNT and RUNXI domains are encoded mainly by exons 3 to 5 and exon 8, respectively (Figure 3). The partial conservation of RUNX1 transcript sequence (exons 5 to 8) and a new folding could explain conformational changes and the absence of RUNT and RUNXI domains.
###end p 47
###begin p 48
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genomic rearrangements involve <italic>USP16 </italic>and <italic>RUNX1 </italic>genes in CMML patients</bold>
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 188 194 188 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 328 333 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1</italic>
###xml 362 374 362 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 391 404 391 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16, RUNX1 </italic>
###xml 408 420 408 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 572 578 572 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 632 644 632 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 648 654 648 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 747 752 747 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB </italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 469 477 <span type="species:ncbi:9606">patients</span>
###xml 741 746 <span type="species:ncbi:9606">human</span>
Genomic rearrangements involve USP16 and RUNX1 genes in CMML patients. A: CMML 88 aCGH profile of chromosome 21 shows regional deletions in 21q21.3 and 21q22.12. Arrows point to USP16 and RUNX1 genes targeted by transition profiles located in these respective regions. This suggests that potential gene breaks involve USP16 and RUNX1. B: PCR characterization of USP16-RUNX1 fusions in CMML. USP16, RUNX1 and USP16-RUNX1 transcripts were detected in the BM cells of the patients. The size of amplified products is shown on the right. The existence of alternatively spliced RUNX1 products could explain the various sizes observed for USP16-RUNX1 and RUNX1 transcripts. cDNA of normal lymphocytes were used as control. Primers specific for the human GUSB transcript were used for control of the RT-PCR quality control.
###end p 48
###begin p 49
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>USP16-RUNX1 </italic>rearrangement in CMML 88</bold>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 403 413 403 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 are </italic>
###xml 489 501 489 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16-RUNX1 </italic>
###xml 631 637 631 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USP16 </italic>
###xml 641 646 641 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1</italic>
USP16-RUNX1 rearrangement in CMML 88. Organization of chromosomal region 21q21.3-q22.12 with the location of the breakpoints (BP) and deleted regions from centromere (cen) to telomere (tel). Mb scale of the corresponding 21q21.3, 21q22.11 and 21q22.12 regions corresponds to cytogenetic bands. Only genes flanking affected regions are reported on the figure. Breakpoints BP1 and BP3 targeting USP16 and RUNX1 are associated with deletions defined by intervals [BP1-BP2] and [BP3-BP4]. The USP16-RUNX1 gene fusion is explained by the inversion of the central interval [BP2-BP3]. ATG codons are in exon 2 (ex 2) and exon 1 (ex 1) of USP16 and RUNX1, respectively.
###end p 49
###begin p 50
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
In total, RUNX1 was altered by mutation (9) or break (2) in 11 patients (8 CMMLs and 3 AT-CMMLs) (Table 2).
###end p 50
###begin p 51
Summary of results.
###end p 51
###begin p 52
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 174 181 <span type="species:ncbi:9606">patient</span>
RAS pathway mutations include point mutations in KRAS, NRAS and PTPN11. RUNX1 alterations include RUNX1 mutations and breaks. Two cases (1 AT and 1 non-AT) are from the same patient.
###end p 52
###begin p 53
###xml 154 166 154 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NUP98-DDX10 </italic>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 203 220 203 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRDM16/MEL1-RPN1 </italic>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Unsurprisingly, the 11q inversion in case 52 and the balanced t(1;3)(p36;q21) in case 90 escaped aCGH detection. The 11q inversion was probably a case of NUP98-DDX10 fusion [18] and the t(1;3) a case of PRDM16/MEL1-RPN1 fusion [19].
###end p 53
###begin title 54
Different alterations in MP- and MD-CMML
###end title 54
###begin p 55
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
Excluding the 6 AT-CMMLs, RAS and PTPN11 mutations were found in 6 of the 13 MP-CMMLs (~46%) whereas no such mutation was found in the 11 MD-CMMLs (Table 2). In contrast, RUNX1 mutations occurred in both MP- (5 cases) or MD-CMML (3 cases).
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX </italic>
We have established the first high resolution genome profiling of CMML and found a high frequency of RAS and RUNX gene alterations.
###end p 57
###begin title 58
CMML and the RAS pathway
###end title 58
###begin p 59
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF1 </italic>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1</italic>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF1 </italic>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 816 823 816 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 903 907 903 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 909 926 909 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOS1, RAF1, BRAF </italic>
###xml 993 995 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1002 1004 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1249 1251 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
In the majority of cases the aCGH profiles did not show any alteration. This suggests that rearrangements and copy number aberrations are not prominent in CMML and that aCGH is only in part suited for obtaining further insight into the pathogenesis of this disease. However, in a small proportion of the cases aCGH was informative, pointing to known tumor suppressor genes such as NF1 and RB1. However, neither gene was mutated in the remaining allele. Deletion of NF1 was particularly interesting since it led us to suspect an alteration of the RAS pathway and a similarity with juvenile myelomonocytic leukemia (JMML). JMML is a chronic myelomonocytic disease that occurs early in life, often on a genetic background of NS, and neurofibromatosis type 1. [20-22]. Half of NS are caused by germline mutations in the PTPN11 gene, which encodes a RAS pathway-regulating phosphatase. Germline mutations in KRAS, SOS1, RAF1, BRAF and other genes of the RAS pathway account for the other NS cases [14,15,20,23]. Syndromes caused by a hyperactivation of the RAS pathway also include Costello, cardio-facio-cutaneous (CFC), hereditary gingival fibromatosis and LEOPARD syndromes, and are collectively called neuro-cardio-facial-cutaneous (NCFC) syndromes [24].
###end p 59
###begin p 60
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NRAS </italic>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS </italic>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 517 521 517 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 777 784 777 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 880 887 880 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 964 966 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1083 1088 1083 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HRAS </italic>
###xml 1176 1180 1176 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HRAS</italic>
###xml 1348 1350 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1486 1488 1486 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1489 1491 1489 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
###xml 640 647 <span type="species:ncbi:9606">patient</span>
We thus sequenced genes coding for proteins involved in the RAS signaling pathway and a RAS mutation was found in four cases (~14%), including a codon 146 mutation in KRAS. In a recent study of CMML, mutations of KRAS and NRAS genes were found in 9 patients out of 32 [25]; two of the six KRAS mutations were in codon 146. It is thus possible that mutation at this site is more frequent than expected, at least in hematopoietic diseases. Germline mutations of KRAS have been found in NCFC syndromes [24,26]. Germline RAS mutations induce precursor lesions and especially myeloproliferative disorders that resemble JMML and CMML [27-29]. In patient 79 the KRAS p.Gly12Ser substitution was present in the myeloid and B lymphoid lineages but not in T cells. We found mutations of PTPN11 exon 3 in 2 cases and exon 13 in one case (other exons were not screened). Somatic mutations of PTPN11 occur in approximately one-third of JMMLs but are less frequent in CMMLs [30,31]. Our combined results indicate that mutations in the RAS pathway occurred in at least one-fourth of CMML cases. No HRAS mutation was detected, in agreement with the absence of hematological manifestations in HRAS-linked Costello syndrome. CMML (at least MP-CMML) shares molecular features with JMML, i.e. similar non-specific alterations of chromosomes 7, 8 and 20, gene fusions [32] and alterations of genes suggesting activation of the RAS pathway. Inhibitors of the RAS pathway might be efficient in treating CMML [33,34].
###end p 60
###begin title 61
CMML and RUNX1 alterations
###end title 61
###begin p 62
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 555 557 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 578 583 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1</italic>
Two cases showed a break in RUNX1 due to an inversion of chromosomal region 21q21-22. RUNX1 encodes the DNA-binding, alpha subunit of the core binding factor (CBF) and is viewed as a tumor suppressor gene whose haplo-insufficiency or dominant-negative mutations play a role in leukemogenesis [35,36]. The gene is also frequently involved in translocations, with more than 15 different partners [37,38]. CBFB is the beta subunit of the heterodimeric CBF factor. CBF regulates hematopoietic stem cell behavior and is essential for definitive hematopoiesis [39]. We show here that RUNX1, already known as a major translocation breakpoint, may even be more frequently altered than thought. Indeed, the 21q inversion is not detectable by karyotyping and, if not for the interstitial microdeletion, would not be detected by aCGH.
###end p 62
###begin p 63
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
RUNX1 mutations were frequent in our series of CMML. In contrast to RAS pathway mutations, mutations of RUNX1 have been reported unfrequently in CMML and JMML, perhaps due to the experimental approach [40]. Overall, we found alterations of RUNX1 in roughly half of the non-acutely transformed cases. They resulted in various truncated or aberrant proteins that could act as dominant-negative isoforms or result in haplo-insufficiency.
###end p 63
###begin p 64
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALN1</italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK6 </italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
Case 12 shows a deletion of CALN1, encoding calneuron 1, a calmodulin-like protein. Calmodulin regulates calcineurin, which is recruited by RUNX1 to regulate granulocyte-macrophage colony-stimulating factor [41]. Finally, CDK6, whose gene is amplified in case 3, inhibits RUNX1 activity [42]. Noticeably, amplification of CDK6 has been recently described in lymphoma [43]. Thus, alteration of RUNX1 function may occur frequently and by different mechanisms in CMML.
###end p 64
###begin title 65
Other alterations
###end title 65
###begin p 66
###xml 135 147 135 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NUP98-DDX10 </italic>
###xml 194 201 194 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDRM16 </italic>
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPN1</italic>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 52 had been treated for breast cancer and the CMML may be due to a therapy-related pericentric inversion of chromosome 11 with NUP98-DDX10 fusion. CMML 90 may be due to a fusion between PDRM16 (EVI1-like) and RPN1. Such fusion is found in MDS and AML-M4 [44].
###end p 66
###begin p 67
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 211 218 211 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
Not surprisingly, CMML shares molecular features with MDS and AML, especially therapy-related diseases, including loss or partial deletions of chromosome 7, rearrangement of the RUNX1 gene, mutations of RAS and PTPN11 [45].
###end p 67
###begin title 68
Cooperative and exclusive alterations
###end title 68
###begin p 69
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF1 </italic>
###xml 180 187 180 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN11 </italic>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOS1 </italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOS1 </italic>
RAS pathway mutations and RUNX1 alterations were not mutually exclusive. RAS mutations, PTPN11 mutations and NF1 deletion were mutually exclusive. However, in case 1, mutations of PTPN11 and SOS1 were found. The two mutations could synergize but the SOS1 mutation has never been reported and its functional relevance remains unknown.
###end p 69
###begin title 70
Myeloproliferative vs myelodysplastic CMML
###end title 70
###begin p 71
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 542 546 542 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Six RAS pathway alterations were found in 13 MP-CMMLs but none in 11 MD-CMMLs (p = 0.016, Fisher exact test). An even higher proportion of MP-CMMLs may be due to mutation in the RAS pathway because other cases could be due to mutations occurring elsewhere in these genes or in other genes of the RAS pathway. This suggests that MP- and MD-CMMLs could develop along two different oncogenic pathways, specific of two distinct diseases. This hypothesis reinforces our previous observation on CMML gene expression [8]. However, in a recent study RAS mutations were distributed independently of the white blood cell count [25].
###end p 71
###begin p 72
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 353 359 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
RB1 deletion, RUNX1 mutation and inv(11)(p15q22) were the only identified alterations in our series of MD-CMML. These alterations are neither specific of CMML nor of MD-CMML (p = non significant) since we found several (5/13) alterations of RUNX1 in MP-CMMLs. Thus, the molecular biology of MD-CMML remains unclear. Yet, we now know that MD-CMML shares RUNX1 alteration with other diseases. It is tempting to speculate that RUNX1 alterations are responsible for the dysplasia whereas RAS pathway mutations are responsible for the myeloproliferation. In terms of treatment, CMMLs with a RAS pathway mutation may benefit from drugs able to target the RAS/RAF/MAPK pathway [33,34] (e.g. sorafenib), while all CMMLs may benefit from therapy restoring RUNX function.
###end p 72
###begin title 73
Conclusion
###end title 73
###begin p 74
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
We have identified two important features of the molecular biology of CMML: i) - RAS pathway mutations are involved, at least, in roughly half of MP-CMML; ii) - RUNX1 alterations are frequent in CMML; they may result from mutations or chromosome rearrangements. Importantly, RAS and RUNX1 alterations are not exclusive, showing that, already, two oncogenic hits may coexist at this chronic stage.
###end p 74
###begin title 75
Competing interests
###end title 75
###begin p 76
The authors declare that they have no competing interests.
###end p 76
###begin title 77
Authors' contributions
###end title 77
###begin p 78
VGB, CA, DS, NV and MJM selected the cases and provided and reviewed the clinical and biological data. VT, NA, VR, SP, CH, MBA and SO generated the sequencing data. JA, VT and MC generated the aCGH data. JA discovered and studied the USP16-RUNX1 fusion. VGB, MJM, DB and MC supervised the study and wrote the manuscript. All authors approved the study and the manuscript.
###end p 78
###begin title 79
Pre-publication history
###end title 79
###begin p 80
The pre-publication history for this paper can be accessed here:
###end p 80
###begin p 81

###end p 81
###begin title 82
Supplementary Material
###end title 82
###begin title 83
Additional File 1
###end title 83
###begin p 84
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Clinical and hematological features of the studied CMMLs.</bold>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 210 217 <span type="species:ncbi:9606">patient</span>
Clinical and hematological features of the studied CMMLs. This table provides details on disease and patients. CMMLs are classified by a double line according to antecedents. Samples 3 and 37 are from the same patient. CMML: chronic myelomonocytic leukemia. In bold: myeloproliferative CMML and corresponding WBC. AT-CMML(AML-M4): acute transformation of CMML in acute myeloid leukemia of M4 FAB type. MDS: myelodysplasic syndromes. RARS: refractory anemia with ring sideroblasts. EPO: erythropoietin. WBC: white blood cell count. TA: therapeutic abstention. DGP: dysgranulopoiesis, DMK: dysmegakaryocytopoiesis, DEP: dyserythropoiesis. 2, 95, 75: hematological malignancies were concomitant of the diagnosis of CMML. 8*: thrombopenia with a diagnosis of MDS (not done in our Institute). Apparition of anemia 2 weeks before the sampling and then treated with EPO. Variable monocytosis around 1.2 G/L but unlikely below 1 G/L at the time of sampling. 25*: persistant and stable monocytosis since June 2006 (1.2 G/L) but unlikely below 1 G/L at the time of sampling. 63*: mild anemia and thrombopenia with a diagnosis of MDS (not done in our Institute) and then under surveillance. 74*: treated for AML (not in our Institute) in 1992 (chemotherapy) and relapse (AML-M5) in our Institute in 2005 (chemotherapy). The cytological aspect of the bone marrow in January 2007 was CMML type 2. 34*: because of the important bone marrow dysplasia and the imprtant cellularity the diagnosis of a acute phase of CMML was made. 80*: antecedent of monocytosis non explored. 88*: thrombopenia since 2005 and diagnosis of CMML (2006) made out of our Institute. 106*: stable monocytosis since February 2000. One sister with breast cancer. One brother with head and neck cancer and her mother with colon cancer (deceased).
###end p 84
###begin p 85
Click here for file
###end p 85
###begin title 86
Additional File 2
###end title 86
###begin p 87
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Conditions of DNA sequencing used in this study for various genes.</bold>
Conditions of DNA sequencing used in this study for various genes. the table provides information (primers, PCR conditions) on sequence experiments conducted in this study.
###end p 87
###begin p 88
Click here for file
###end p 88
###begin title 89
Additional File 3
###end title 89
###begin p 90
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Primers used for PCR detection of <italic>RUNX1 </italic>alteration.</bold>
Primers used for PCR detection of RUNX1 alteration. The table provides information of primers used to detect USP16-RUNX1 fusion.
###end p 90
###begin p 91
Click here for file
###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
###xml 23 31 <span type="species:ncbi:9606">patients</span>
We are grateful to the patients who participated in this study. The work has been supported by Inserm, Institut Paoli-Calmettes, and grants from Institut National du Cancer (PHRC 2005 ndegrees 24-33, NV), Caisse Primaire d'Assurance Maladie des Professions Liberales de Province (2006, MC), Association pour la Recherche contre le Cancer (ARC Sud 2007, DB) and Fondation de France (comite Leucemie, 2007, DB).
###end p 93
###begin article-title 94
The world health classification (WHO) of myeloid neoplasms
###end article-title 94
###begin article-title 95
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group
###end article-title 95
###begin article-title 96
Problems in the classification of CMML-dysplastic versus proliferative type
###end article-title 96
###begin article-title 97
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Dysplastic versus proliferative CMML-a retrospective analysis of 91 patients from a single institution
###end article-title 97
###begin article-title 98
Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center
###end article-title 98
###begin article-title 99
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Pronostics factors in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
###end article-title 99
###begin article-title 100
Chronic myelomonocytic leukemia in the light of the WHO proposals
###end article-title 100
###begin article-title 101
Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes
###end article-title 101
###begin article-title 102
Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes
###end article-title 102
###begin article-title 103
Integrated profiling of basal and luminal breast cancers
###end article-title 103
###begin article-title 104
Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA
###end article-title 104
###begin article-title 105
A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion
###end article-title 105
###begin article-title 106
###xml 38 43 <span type="species:ncbi:9606">human</span>
Recurrent KRAS codon 146 mutations in human colorectal cancer
###end article-title 106
###begin article-title 107
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy
###end article-title 107
###begin article-title 108
Germline gain-of-function mutations in RAF1 cause Noonan syndrome
###end article-title 108
###begin article-title 109
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
###end article-title 109
###begin article-title 110
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype
###end article-title 110
###begin article-title 111
The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10
###end article-title 111
###begin article-title 112
A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells
###end article-title 112
###begin article-title 113
Noonan syndrome and related disorders: genetics and pathogenesis
###end article-title 113
###begin article-title 114
Neurofibromatosis 1
###end article-title 114
###begin article-title 115
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
###end article-title 115
###begin article-title 116
Hyperactive Ras in developmental disorders and cancer
###end article-title 116
###begin article-title 117
###xml 31 36 <span type="species:ncbi:9606">human</span>
Stops along the RAS pathway in human genetic disease
###end article-title 117
###begin article-title 118
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia
###end article-title 118
###begin article-title 119
###xml 75 80 <span type="species:ncbi:9606">human</span>
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
###end article-title 119
###begin article-title 120
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects
###end article-title 120
###begin article-title 121
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder
###end article-title 121
###begin article-title 122
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations
###end article-title 122
###begin article-title 123
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
###end article-title 123
###begin article-title 124
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
###end article-title 124
###begin article-title 125
HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2)
###end article-title 125
###begin article-title 126
Targeting RAS signaling pathways in juvenile myelomonocytic leukemia
###end article-title 126
###begin article-title 127
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11
###end article-title 127
###begin article-title 128
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
###end article-title 128
###begin article-title 129
Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis
###end article-title 129
###begin article-title 130
###xml 0 10 <span type="species:ncbi:111938">Gatekeeper</span>
Gatekeeper function of the RUNX1 transcription factor in acute leukemia
###end article-title 130
###begin article-title 131
The impact of translocations and gene fusions on cancer causation
###end article-title 131
###begin article-title 132
AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis
###end article-title 132
###begin article-title 133
Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia
###end article-title 133
###begin article-title 134
AML1/Runx1 recruits calcineurin to regulate granulocyte macrophage colony-stimulating factor by Ets1 activation
###end article-title 134
###begin article-title 135
Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction
###end article-title 135
###begin article-title 136
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma
###end article-title 136
###begin article-title 137
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5' region of MEL1
###end article-title 137
###begin article-title 138
Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations
###end article-title 138

